Eylea biosimilars from Amgen and Samsung are eating their lunch. Base Eylea sales fell like 25% last quarter, and that franchise used to be 40% of their revenue. Luckily, Dupixent is still a monster. Almost $18 billion in global sales last year, up... — read more
Expensive but worth it
Regeneron seems to be one of the most stable constant climbers lately. I know it's expensive right now, but in my opinion, well worth it. Just look at its latest earnings report. Plus, with products like Eylea and Dupixent, I don't think there's a... — read more